HHS and NIH Unveil Next-Generation Universal Vaccine Platform
Colorized transmission electron micrograph of influenza A/H1N1 virus particles.
Today, the U.S. Department of Health and Human Services (HHS) alongside the National Institutes for Health (NIH) unveiled their latest advancement: the next-generation, universal vaccine platform known as Generation Gold Standard. This innovative approach employs a beta-propiolactone (BPL)-inactivated, whole-virus method.
This programme marks a significant move towards greater openness, efficiency, and thorough readiness. It provides financial backing for the NIH’s internal work on universal flu and coronavirus vaccines, specifically looking at candidate vaccines like BPL-1357 and BPL-24910. The objective is to create immunisations that offer extensive defence against various strains of high-risk viruses, including H5N1 bird flu and different types of coronaviruses such as SARS-CoV-2, SARS-CoV-1, and MERS-CoV.
Our dedication is straightforward: each advancement in vaccine creation needs to be rooted in top-tier scientific methods and openness, along with rigorous adherence to the strictest safety and effectiveness evaluations.
Robert F. Kennedy, Jr., Health and Human Services Secretary
Find the complete tale here .
Post a Comment for "HHS and NIH Unveil Next-Generation Universal Vaccine Platform"
Post a Comment